Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms JNJ 78278343, JNJ-78278343 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), KLK2 inhibitors(Kallikrein 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 1 | US | 26 Apr 2023 | |
Metastatic castration-resistant prostate cancer | Phase 1 | AU | 26 Apr 2023 | |
Advanced Prostate Carcinoma | Phase 1 | US | 13 Jul 2021 | |
Advanced Prostate Carcinoma | Phase 1 | FR | 13 Jul 2021 | |
Advanced Prostate Carcinoma | Phase 1 | NL | 13 Jul 2021 | |
Advanced Prostate Carcinoma | Phase 1 | ES | 13 Jul 2021 | |
Castration-Resistant Prostatic Cancer | Phase 1 | FR | 13 Jul 2021 | |
Castration-Resistant Prostatic Cancer | Phase 1 | NL | 13 Jul 2021 | |
Castration-Resistant Prostatic Cancer | Phase 1 | ES | 13 Jul 2021 |